Levis, M. J., Hamadani, M., Logan, B. R., Jones, R. J., Singh, A. K., Litzow, M. R., Wingard, J. R., Papadopoulos, E. B., Perl, A. E., Soiffer, R. J., Ustun, C., Oshima, M. U., Uy, G. L., Waller, E. K., Vasu, S., Solh, M., Mishra, A., Muffly, L. S., Kim, H., Stelljes, M., Najima, Y., Onozawa, M., Thomson, K., Nagler, A., Wei, A. H., Marcucci, G., Chen, C., Hasabou, N., Rosales, M., Hill, J., Gill, S. C., Nuthethi, R., King, D., Mendizabal, A., Devine, S. M., Horowitz, M. M., Chen, Y. (2025). Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD–mutated AML. Blood. https://doi.org/10.1182/blood.2024025154